- Home
- BABA vs NVO Comparison
BABA vs NVO Comparison
Compare BABA & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BABA
- NVO
- Stock Information
- Founded
- BABA 1999
- NVO 1923
- Country
- BABA Hong Kong
- NVO Denmark
- Employees
- BABA N/A
- NVO N/A
- Industry
- BABA Business Services
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BABA Consumer Discretionary
- NVO Health Care
- Exchange
- BABA Nasdaq
- NVO Nasdaq
- Market Cap
- BABA 273.3B
- NVO 278.0B
- IPO Year
- BABA 2014
- NVO N/A
- Fundamental
- Price
- BABA $108.55
- NVO $69.13
- Analyst Decision
- BABA Strong Buy
- NVO Buy
- Analyst Count
- BABA 14
- NVO 3
- Target Price
- BABA $153.62
- NVO $112.00
- AVG Volume (30 Days)
- BABA 11.7M
- NVO 8.6M
- Earning Date
- BABA 08-14-2025
- NVO 08-06-2025
- Dividend Yield
- BABA 0.97%
- NVO 1.71%
- EPS Growth
- BABA 71.52
- NVO 17.93
- EPS
- BABA 7.39
- NVO 3.40
- Revenue
- BABA $137,304,072,265.00
- NVO $43,922,211,349.00
- Revenue This Year
- BABA $8.77
- NVO $18.59
- Revenue Next Year
- BABA $8.09
- NVO $15.61
- P/E Ratio
- BABA $14.72
- NVO $20.87
- Revenue Growth
- BABA 5.86
- NVO 24.11
- 52 Week Low
- BABA $72.95
- NVO $57.00
- 52 Week High
- BABA $148.43
- NVO $143.69
- Technical
- Relative Strength Index (RSI)
- BABA 34.77
- NVO 44.67
- Support Level
- BABA $111.40
- NVO $68.12
- Resistance Level
- BABA $114.79
- NVO $70.42
- Average True Range (ATR)
- BABA 1.98
- NVO 1.47
- MACD
- BABA -0.38
- NVO -0.73
- Stochastic Oscillator
- BABA 7.89
- NVO 15.79
About BABA Alibaba Group Holding Limited
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.